Physician profile
Boyde Jerome Harrison
NPI 1619908571
$29,238.92
in general payments reported to CMS, 2019-2025
43 companies · $836 in 2025
The $836 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $3,691 · 2021: $5,013 · 2022: $1,665 · 2023: $6,770 · 2024: $1,008 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,000 · Food and Beverage: $3,567 · Travel and Lodging: $1,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,000.00 |
| Food and Beverage | $3,566.79 |
| Travel and Lodging | $1,047.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $9,453.51 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $8,099.50 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Gilead Sciences, INC. | $5,883.29 | 2019-2025 | Epclusa |
| Novartis Pharmaceuticals Corporation | $732.98 | 2019-2025 | |
| Abbvie INC. | $679.78 | 2020-2025 | |
| Indivior INC. | $572.82 | 2019-2025 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $539.69 | 2022-2025 | Rexulti |
| Amgen INC. | $324.24 | 2020-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $297.34 | 2022-2025 | Verquvo, Belsomra |
| Janssen Pharmaceuticals, INC | $266.41 | 2019-2021 | |
| Pfizer INC. | $258.19 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $249.96 | 2023 | Nuplazid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $240.34 | 2019-2025 | Xifaxan |
| Braeburn INC. | $166.85 | 2023-2025 | Brixadi |
| Teva Pharmaceuticals USA, INC. | $165.63 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
Show all 42 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boyde Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.